BioMarin Pharmaceutical Inc. (BMRN)
After hours:
| Previous close | 115.35 |
| Open | 115.05 |
| Bid | 113.45 x 1400 |
| Ask | 116.86 x 800 |
| Day's range | 114.25 - 116.86 |
| 52-week range | 70.73 - 117.77 |
| Volume | |
| Avg. volume | 1,536,053 |
| Market cap | 21.69B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 277.88 |
| EPS (TTM) | 0.42 |
| Earnings date | 21 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 122.14 |
- Zacks
Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Motley Fool
2 Top Biotech Stocks Defying the Bear Market
The SPDR S&P Biotech ETF is down 20% over the past year. In fact, BioMarin Pharmaceuticals (NASDAQ: BMRN) and Novo Nordisk (NYSE: NVO) are at their highest levels in a year. The company was founded in 1997 to develop treatments for extremely rare genetic diseases.
- PR Newswire
BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced positive results from more than three years of follow up from its ongoing global Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec), an investigational one-time gene therapy for the treatment of adults with severe hemophilia A. This is the largest and longest global Phase 3 study to date for any gene therapy in hemophilia with 134
